Cargando…

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins

The routine monitoring of direct oral anticoagulants (DOACs) may be considered in patients with renal impairment, patients who are heavily obese, or patients requiring elective surgery. Using the heparin-binding copolymer (HBC) and polybrene, we aimed to develop a solution for monitoring the anticoa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakimczuk, Aleksandra, Kalaska, Bartlomiej, Kamiński, Kamil, Miklosz, Joanna, Yusa, Shin-Ichi, Pawlak, Dariusz, Szczubiałka, Krzysztof, Mogielnicki, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028841/ https://www.ncbi.nlm.nih.gov/pubmed/35456329 http://dx.doi.org/10.3390/jcm11082236

Ejemplares similares

The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target
por: Kalaska, Bartlomiej, et al.
Publicado: (2019)

Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice
por: Swieton, Justyna, et al.
Publicado: (2021)

The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents
por: Miklosz, Joanna, et al.
Publicado: (2019)

The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats
por: Kalaska, Bartlomiej, et al.
Publicado: (2022)

The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review
por: Frackiewicz, Aleksandra, et al.
Publicado: (2023)

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin
por: Kalaska, Bartlomiej, et al.
Publicado: (2015)

The Toxicokinetic Profile of Dex40-GTMAC3—a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin
por: Sokolowska, Emilia, et al.
Publicado: (2016)

Monitoring of Cardiorespiratory Parameters in Rats—Validation Based on Pharmacological Stimulation
por: Miklosz, Joanna, et al.
Publicado: (2021)

Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch
por: Stolarek, Marta, et al.
Publicado: (2023)

Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models
por: Miklosz, Joanna, et al.
Publicado: (2021)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
por: Úlehlová, Jana, et al.
Publicado: (2021)

Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
por: Yin, Lu, et al.
Publicado: (2022)

Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography
por: Artang, Ramin, et al.
Publicado: (2021)

Inactivation of Heparin by Cationically Modified Chitosan
por: Lorkowska-Zawicka, Barbara, et al.
Publicado: (2014)

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
por: Ru San, Tan, et al.
Publicado: (2012)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
por: Al-Ghafry, Maha, et al.
Publicado: (2022)

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
por: Winkle, Roger A., et al.
Publicado: (2014)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice
por: Buijs, Jeroen T., et al.
Publicado: (2019)

Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban
por: Lin, Yu‐Sheng, et al.
Publicado: (2021)

The Effects of Dabigatran and Rivaroxaban on Markers of Polymorphonuclear Leukocyte Activation
por: Richards, Guy A., et al.
Publicado: (2018)

Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next?
por: Mor, Adrian, et al.
Publicado: (2020)

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
por: Lip, Gregory Y. H., et al.
Publicado: (2018)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012)

Heparin dosing in uninterrupted anticoagulation with dabigatran vs. warfarin in atrial fibrillation ablation: RE-CIRCUIT study
por: Calkins, Hugh, et al.
Publicado: (2019)

Self-Organized Nanoparticles of Random and Block Copolymers of Sodium 2-(Acrylamido)-2-methyl-1-propanesulfonate and Sodium 11-(Acrylamido)undecanoate as Safe and Effective Zika Virus Inhibitors
por: Botwina, Pawel, et al.
Publicado: (2022)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Dabigatran approaching the realm of heparin-induced thrombocytopenia
por: Ho, Patricia J, et al.
Publicado: (2016)

Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin – a model-based study
por: Edrich, Thomas, et al.
Publicado: (2015)

Length of hospitalization and mortality for bleeding during treatment with warfarin, dabigatran, or rivaroxaban
por: Charlton, Blake, et al.
Publicado: (2018)

Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report
por: Sun, Huan, et al.
Publicado: (2018)

Anticoagulant Related Nephropathy Induced by Dabigatran
por: Sharfuddin, Nazia, et al.
Publicado: (2018)

Neurobehavioral effects of uremic toxin–indoxyl sulfate in the rat model
por: Karbowska, Malgorzata, et al.
Publicado: (2020)

Suspected Rivaroxaban-Induced Anaphylaxis Secondary to Ingestion of Rivaroxaban and Nimesulide Without Cross-Reactivity to Dabigatran – A Case Report
por: Gumbis, Gediminas, et al.
Publicado: (2023)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n8u84tmp898ipka0eac921ahko